MARKET

AEMD

AEMD

Aethlon Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2940
+0.0039
+1.34%
After Hours: 0.2800 -0.014 -4.76% 16:21 09/18 EDT
OPEN
0.3039
PREV CLOSE
0.2901
HIGH
0.3100
LOW
0.2800
VOLUME
95.43K
TURNOVER
--
52 WEEK HIGH
1.740
52 WEEK LOW
0.2025
MARKET CAP
5.79M
P/E (TTM)
-0.7632
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AEMD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AEMD News

  • Aethlon Medical Receives National Cancer Institute Contract Award
  • PR Newswire.2d ago
  • Aethlon Medical Reports Received National Cancer Institute Contract Award For $1.86M
  • Benzinga.2d ago
  • Aethlon Medical Shares Volatile On Uptick In Volume As Traders Circulate Doc From Federal Procurement Data System Showing Recently-Dated $1.86M Contract By National Institutes Of Health For Co.
  • Benzinga.5d ago
  • Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q1 2020 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.08/15 00:08

More

Industry

Medical Equipment, Supplies & Distribution
-0.01%
Healthcare Equipment & Supplies
+0.17%

Hot Stocks

Name
Price
%Change

About AEMD

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.
More

Webull offers Aethlon Medical, Inc. (AEMD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.